Kimberly-Clark (KMB) 10-Q23 Apr 242024 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	Apr. 16, 2024
Entity Information [Line Items]
Document Type	10-Q
Document Period End Date	Mar. 31, 2024
Entity File Number	1-225
Entity Registrant Name	KIMBERLY-CLARK CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	39-0394230
Entity Address, Address Line One	P.O. Box 619100
Entity Address, City or Town	Dallas,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75261-9100
City Area Code	(972)
Local Phone Number	281-1200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		336,709,077
Document Quarterly Report	true
Document Transition Report	false
Entity Shell Company	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000055785
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Common Stock \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	KMB
Security Exchange Name	NYSE
0.625% Notes Due 2024 [Member] \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.625% Notes due 2024
Trading Symbol	KMB24
Security Exchange Name	NYSE

Consolidated Income Statement

Consolidated Income Statement - USD ($) $ in Millions	3 Months Ended
Consolidated Income Statement - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Sales	$ 5,149	$ 5,195
Cost of products sold	3,238	3,469
Gross Profit	1,911	1,726
Marketing, research and general expenses	1,039	924
Other (income) and expense, net	19	15
Operating Profit	853	787
Nonoperating expense	(15)	(16)
Interest income	10	7
Interest expense	(67)	(73)
Income Before Income Taxes and Equity Interests	781	705
Provision for income taxes	(184)	(173)
Income Before Equity Interests	597	532
Share of net income of equity companies	61	43
Net income	658	575
Net income attributable to noncontrolling interests	(11)	(9)
Net Income Attributable to Kimberly-Clark Corporation	$ 647	$ 566
Per Share Basis
Basic	$ 1.92	$ 1.68
Diluted	$ 1.91	$ 1.67

Consolidated Statement Of Compr

Consolidated Statement Of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net Income	$ 658	$ 575
Other Comprehensive Income (Loss), Net of Tax
Unrealized currency translation adjustments	(149)	93
Employee postretirement benefits	11	(8)
Cash flow hedges and other	63	(78)
Total Other Comprehensive Income (Loss), Net of Tax	(75)	7
Comprehensive Income	583	582
Comprehensive income attributable to noncontrolling interests	(8)	(8)
Comprehensive Income Attributable to Kimberly-Clark Corporation	$ 575	$ 574

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) shares in Millions, $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 853	$ 1,093
Accounts receivable, net	2,383	2,135
Inventories	1,877	1,955
Other current assets	487	520
Total Current Assets	5,600	5,703
Property, Plant and Equipment, Net	7,772	7,913
Investments in Equity Companies	364	306
Goodwill	2,043	2,085
Other Intangible Assets, Net	190	197
Other Assets	1,123	1,140
TOTAL ASSETS	17,092	17,344
Current Liabilities
Debt payable within one year	809	567
Trade accounts payable	3,531	3,653
Accrued expenses and other current liabilities	2,131	2,316
Dividends payable	407	394
Total Current Liabilities	6,878	6,930
Long-Term Debt	7,161	7,417
Noncurrent Employee Benefits	652	669
Deferred Income Taxes	395	374
Other Liabilities	796	860
Redeemable Preferred Securities of Subsidiaries	$ 26	$ 26
Preferred Stock, Shares Issued	0	0
Stockholders' Equity
Preferred Stock, Value, Issued	$ 0	$ 0
Common Stock, Value, Issued	473	473
Equity, Attributable to Parent, Total	1,044	915
Noncontrolling Interests	140	153
Total Stockholders' Equity	1,184	1,068
Treasury Stock, Value [Abstract]
Treasury Stock, Value	(5,252)	(5,222)
Additional Paid in Capital [Abstract]
Additional Paid in Capital	877	878
Retained Earnings (Accumulated Deficit) [Abstract]
Retained Earnings (Accumulated Deficit)	8,601	8,368
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	17,092	17,344
Accumulated Other Comprehensive Income (loss)	$ (3,655)	$ (3,582)

Consolidated Balance Sheet Pare

Consolidated Balance Sheet Parenthetical - USD ($) shares in Millions, $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share	$ 0	$ 0
Preferred Stock, Shares Authorized	20	20
Preferred Stock, Shares Issued	0	0
Common Stock, Par or Stated Value Per Share	$ 1.25	$ 1.25
Common Stock, Shares Authorized	1,200	1,200
Common Stock, Shares, Issued	378.6	378.6
Treasury Stock, Common, Shares	41.8	41.6
Additional Paid in Capital	$ 877	$ 878
Treasury Stock, Value	(5,252)	(5,222)
Retained Earnings (Accumulated Deficit)	8,601	8,368
Accumulated Other Comprehensive Income (loss)	$ (3,655)	$ (3,582)

Statement of Stockholders' Equi

Statement of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	AOCI Attributable to Parent	Noncontrolling Interests	Treasury Stock, Common
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued		$ 473
Additional Paid in Capital			$ 679
Treasury Stock, Value							$ (5,137)
Retained Earnings				$ 8,201
Accumulated Other Comprehensive Income (Loss)					$ 3,669
Noncontrolling Interests						$ 153
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 700
Treasury Stock, Common, Shares							41,135
Net income	575			566
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest						10
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excludes Redeemable Interests' Share	576
Other Comprehensive Income, Net of Tax	(7)				(8)	(3)
Other Comprehensive Income (Loss), Net of Tax, Excludes Redeemable Interests' Share	5
Stock-based awards exercised or vested	6		(12)				$ 18
Treasury Stock, Shares, Acquired							265
Treasury Stock, Value, Acquired, Cost Method							$ (34)
Recognition of stock-based compensation	23		23
Dividends, Common Stock, Cash	(414)			(398)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders						(16)
Other	$ 1		4	(4)	(1)	(2)	$ 0
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures							(169)
Dividends declared	$ 1.18
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued		$ 473
Additional Paid in Capital			694
Treasury Stock, Value							$ (5,153)
Retained Earnings				8,365
Accumulated Other Comprehensive Income (Loss)					3,660
Noncontrolling Interests						142
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 861
Treasury Stock, Common, Shares							41,231
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued	473	$ 473
Additional Paid in Capital	878		878
Treasury Stock, Value	(5,222)						$ (5,222)
Retained Earnings	8,368			8,368
Accumulated Other Comprehensive Income (Loss)	3,582				3,582
Noncontrolling Interests	153					153
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 1,068
Treasury Stock, Common, Shares	41,600						41,599
Net income	$ 658			647
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest						10
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excludes Redeemable Interests' Share	657
Other Comprehensive Income, Net of Tax	75				72	(4)
Other Comprehensive Income (Loss), Net of Tax, Excludes Redeemable Interests' Share	(76)
Stock-based awards exercised or vested	(11)		(37)				$ 26
Treasury Stock, Shares, Acquired							459
Treasury Stock, Value, Acquired, Cost Method							$ (56)
Recognition of stock-based compensation	31		31
Dividends, Common Stock, Cash	(430)			(411)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders						(19)
Other	$ (1)		$ 5	$ (3)	$ 1	0
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures							(235)
Dividends declared	$ 1.22
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued	$ 473	$ 473
Additional Paid in Capital	877
Treasury Stock, Value	(5,252)
Retained Earnings	8,601
Accumulated Other Comprehensive Income (Loss)	3,655
Noncontrolling Interests	140					$ 140
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 1,184
Treasury Stock, Common, Shares	41,800						41,823

Statement of Stockholders' Eq_2

Statement of Stockholders' Equity Stockholders' Equity Parentheticals - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared	$ 1.22	$ 1.18

Consolidated Cash Flow Statemen

Consolidated Cash Flow Statement - USD ($) $ in Millions	3 Months Ended
Consolidated Cash Flow Statement - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Operating Activities
Net income	$ 658	$ 575
Depreciation and amortization	185	188
Asset impairments	0	11
Stock-based compensation	32	24
Deferred income taxes	(11)	(50)
Net (gains) losses on asset dispositions	5	2
Equity companies' earnings (in excess of) less than dividends paid	(61)	(43)
Operating working capital	(367)	(85)
Postretirement benefits	2	(6)
Other	(5)	(3)
Cash Provided by Operations	438	613
Investing Activities
Capital spending	(194)	(201)
Investments in time deposits	(97)	(177)
Maturities of time deposits	119	259
Other	(9)	4
Cash Used for Investing	(181)	(115)
Financing Activities
Cash dividends paid	(398)	(391)
Change in short-term debt	4	(308)
Debt proceeds	0	348
Proceeds from exercise of stock options	3	11
Acquisitions of common stock for the treasury	(54)	(30)
Payments of Ordinary Dividends, Noncontrolling Interest	(19)	(16)
Other	(21)	(11)
Cash Used for Financing	(485)	(397)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(12)	(4)
Change in Cash and Cash Equivalents	(240)	97
Cash and Cash Equivalents - Beginning of Period	1,093	427
Cash and Cash Equivalents - End of Period	$ 853	$ 524

Accounting Policies

Accounting Policies	3 Months Ended
Accounting Policies	Mar. 31, 2024
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. For further information, refer to the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2023. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries. Highly Inflationary Accounting GAAP guidance requires the use of highly inflationary accounting for countries whose cumulative three-year inflation exceeds 100 percent. Under highly inflationary accounting, the countries’ functional currency becomes the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. In the second quarter of 2018, published inflation indices indicated that the three-year cumulative inflation in Argentina exceeded 100 percent, and as of July 1, 2018, we elected to adopt highly inflationary accounting for our subsidiaries in Argentina (“K-C Argentina”). The effect of changes in exchange rates on peso-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net. As of March 31, 2024 , K-C Argentina had an immaterial net peso monetary position. Net sales of K-C Argentina were approximately 1 percent of our consolidated net sales for the three months ended March 31, 2024 and 2023. In the first quarter of 2022, published inflation indices indicated that the three-year cumulative inflation in Türkiye exceeded 100 percent, and as of April 1, 2022, we elected to adopt highly inflationary accounting for our subsidiary in Türkiye (“K-C Türkiye”). The effect of changes in exchange rates on lira-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense , net. As of March 31, 2024, K-C Türkiye h ad an immaterial net lira monetary position. Net sales of K-C Türkiye were les s than 1 perce nt of our consolidated net sales for the three months ended March 31, 2024 and 2023 . Recently Adopted Accounting Standard In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50) . The new guidance requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of the financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. We adopted this ASU as of January 1, 2023, except for the amendment on roll forward information which was adopted January 1, 2024. As the guidance requires only additional disclosure, there were no effects of this standard on our financial position, results of operations or cash flows. Recently Issued Accounting Standards In 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) . The new guidance improves reportable segment disclosures primarily through enhanced disclosures about significant segment expenses and by requiring current annual disclosures to be provided in interim periods. The amendments in this ASU are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new guidance is to be applied retrospectively to all prior periods presented unless impracticable to do so. As the guidance requires only additional disclosure, there will be no effects of this standard on our financial position, results of operations or cash flows. In 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) . The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU are effective for annual periods beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied on a prospective basis with retrospective application permitted. As the guidance requires only additional disclosure, there will be no effects of this standard on our financial position, results of operations or cash flows . In March 2024, the Securities and Exchange Commission (“SEC”) adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors . The rules require disclosure of, among other things: climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition, and material direct greenhouse gas ("GHG") emissions from operations owned or controlled (Scope 1) and /or indirect GHG emissions from purchased energy consumed in operations (Scope 2). Additionally, the rules require disclosure of certain climate-related metrics subject to certain materiality thresholds, including the effects of severe weather events and other natural conditions. Disclosure requirements will begin phasing in prospectively for fiscal years beginning on or after January 1, 2025. Subsequent to issuance, the rules became the subject of litigation, and the SEC has issued a stay to allow the legal process to proceed. We are currently evaluating the impact of the rules on our disclosures and will monitor the litigation progress for possible impacts on the disclosure requirements under the rules .

2024 Transformation Initiative

2024 Transformation Initiative	3 Months Ended
2024 Transformation Initiative	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
2024 Transformation Initiative	2024 Transformation Initiative On March 27, 2024, we announced the 2024 Transformation Initiative intended to improve our focus on growth and reduce our structural cost base by reorganizing into three new business segments, making the corporate and regional overhead cost structures more efficient and optimizing our global supply chain. The transformation is expected to impact our organization in all major geographies, and workforce reductions are expected to be in the range of 4 percent to 5 percent . Certain actions under the transformation initiative are being finalized for implementation, and accounting for such actions will commence when the actions are authorized for execution. We expect to complete the transition to the new organizational structure by the end of 2024, and the transformation initiative is expected to be completed by the end of 2026, with total costs anticipated to be approximately $1.5 billion pre-tax. Cash costs are expected to be approximately half of that amount, primarily related to workforce reductions. Non-cash charges are primarily related to incremental depreciation and asset write-offs. The following charges were incurred in connection with the 2024 Transformation Initiative: Three Months Ended March 31, 2024 Marketing, research and general expenses Charges for workforce reductions $ 23 Other exit costs 22 Total charges 45 Provision for income taxes (11) Net charges attributable to Kimberly-Clark Corporation $ 34 See Note 9 for charges by segment. The following summarizes the transformation initiative liabilities activity for the quarter: 2024 Transformation initiative liabilities at January 1 $ — Charges for workforce reductions and other cash exit costs 45 Cash payments (11) Transformation initiative liabilities at March 31 $ 34

Acquisition

Acquisition	3 Months Ended
Acquisition	Mar. 31, 2024
Business Combinations [Abstract]
Mergers, Acquisitions and Dispositions Disclosures	Acquisition and Divestiture Acquisition On February 24, 2022, we completed our acquisition of a majority and controlling share of Thinx Inc. (“Thinx”), an industry leader in the reusable period and incontinence underwear category, for total consideration of $181. We previously accounted for our ownership interest in Thinx as an equity method investment, but upon increasing our ownership to 58 percent, we began consolidating the operations of Thinx into our financial statements at the end of the first quarter of 2022. In the first quarter of 2023, we delivered a redemption notice to the third-party minority owner with respect to a portion of the remaining common securities of Thinx. The redemption closed in the second quarter of 2023, and we acquired additional ownership of Thinx for $48, increasing our controlling ownership to 70 percent. As part of the completion of a negotiated final redemption, we acquired the remaining 30 percent ownership of Thinx for $47 in the fourth quarter of 2023. As the purchase of additional ownership in an already controlled subsidiary represents an equity transaction, no gain or loss was recognized in consolidated net income or comprehensive income. Divestiture On June 1, 2023, we completed the sale transaction, announced on October 24, 2022, of our Neve tissue brand and related consumer and K-C Professional tissue assets in Brazil for $212. Upon closure of the transaction, a gain of $74 pre-tax was recognized in Other (income) and expense, net. We incurred divestiture-related costs of $30 pre-tax, which were recorded in Cost of products sold and Marketing, research and general expenses, resulting in a net benefit of $44 pre-tax ($26 after tax). See Note 3, Acquisition and Divestiture, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023 for further information related to the Thinx acquisition and Brazil divestiture.

Impairment of Intangible Assets

Impairment of Intangible Assets	3 Months Ended
Impairment of Intangible Assets	Mar. 31, 2024
Text Block [Abstract]
Intangible Assets Disclosure	Impairment of Intangible Assets In the second quarter of 2023, we conducted forecasting and strategic reviews and integration assessments of our Softex Indonesia business, acquired in the fourth quarter of 2020, and with performance below expectations since acquisition, we revised internal financial projections of the business to reflect updated expectations of future financial performance. As a result of separate management reviews, we also have revised internal financial projections associated with our acquisition of a controlling interest in Thinx as a result of performance below expectations. These revisions were considered triggering events requiring interim impairment assessments to be performed relative to the intangible assets that had been recorded as part of these acquisitions. These intangible assets were recorded as part of the Personal Care business segment and included indefinite-lived and finite-lived brands and finite-lived distributor and customer relationships. As a result of the interim impairment assessments, we recognized impairment charges, principally arising from the impairment charge of $593 related to the Softex business, totaling $658 pre-tax ($483 after tax) to write-down these intangible assets to their respective fair values aggregating to $188. See Note 4, Goodwill and Other Intangible Assets, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023 for further information.

Fair Value Information

Fair Value Information	3 Months Ended
Fair Value Information	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Information	Fair Value Information The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are: Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the three months ended March 31, 2024 and for the full year 2023, there were no significant transfers to or from level 3 fair value determinations. Derivative assets and liabilities are measured on a recurring basis at fair value. At March 31, 2024 and December 31, 2023, derivative assets were $84 and $70, respectively, and derivative liabilities were $210 and $259, respectively. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on the Secured Overnight Financing Rate ("SOFR") and interest rate swap curves and on commodity price quotations, respectively. The fair values of hedging instruments used to manage foreign currency risk are based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Measurement of our derivative assets and liabilities is considered a level 2 measurement. Additional information on our classification and use of derivative instruments is contained in Note 8. Redeemable preferred securities of subsidiaries are measured on a recurring basis at their estimated redemption values, which approximate fair value. As of March 31, 2024 and December 31, 2023, the securities were valued at $26. The securities are not traded in active markets, and their measurement is considered a level 3 measurement. Company-owned life insurance ("COLI") assets are measured on a recurring basis at fair value. COLI assets were $69 and $67 at March 31, 2024 and December 31, 2023 , respectively. The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in Other Assets. The COLI policies are measured at fair value using the net asset value per share practical expedient, and therefore, are not classified in the fair value hierarchy. The following table includes the fair value of our financial instruments for which disclosure of fair value is required: Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value March 31, 2024 December 31, 2023 Assets Cash and cash equivalents (a) 1 $ 853 $ 853 $ 1,093 $ 1,093 Time deposits (b) 1 143 143 169 169 Liabilities Short-term debt (c) 2 7 7 2 2 Long-term debt (d) 2 7,963 7,412 7,982 7,569 (a) Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. (b) Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. (c) Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. (d) Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share ("EPS") There are no adjustments required to be made to net income for purposes of computing basic and diluted EPS. The dilutive effect of stock options and other stock-based awards is reflected in diluted EPS by application of the treasury stock method. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows: Three Months Ended (Millions of shares) 2024 2023 Basic 336.9 337.5 Dilutive effect of stock options and restricted share unit awards 1.4 1.1 Diluted 338.3 338.6 Options outstanding that were not included in the computation of diluted EPS because their exercise price was greater than the average market price of the common shares were insignificant. The number of common shares outstanding as of March 31, 2024 and 2023 was 336.8 million and 337.4 million, respectively.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Mar. 31, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation adjustments are recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation. Also included in unrealized translation amounts are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments. The change in net unrealized currency translation for the three months ended March 31, 2024 was primarily due to the weakening of certain foreign currencies versus the U.S. dollar. The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows: Unrealized Translation Defined Benefit Pension Plans Other Postretirement Benefit Plans Cash Flow Hedges and Other Balance as of December 31, 2022 $ (2,769) $ (789) $ 52 $ (163) Other comprehensive income (loss) before reclassifications 95 (14) — (93) (Income) loss reclassified from AOCI — 7 (a) (1) (a) 15 Net current period other comprehensive income (loss) 95 (7) (1) (78) Balance as of March 31, 2023 $ (2,674) $ (796) $ 51 $ (241) Balance as of December 31, 2023 $ (2,678) $ (791) $ 39 $ (152) Other comprehensive income (loss) before reclassifications (144) 3 1 60 (Income) loss reclassified from AOCI — 8 (a) (1) (a) — Net current period other comprehensive income (loss) (144) 11 — 60 Balance as of March 31, 2024 $ (2,822) $ (780) $ 39 $ (92) (a) Included in computation of net periodic benefit costs.

Objectives And Strategies For U

Objectives And Strategies For Using Derivatives	3 Months Ended
Objectives And Strategies For Using Derivatives	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Objectives And Strategies For Using Derivatives	Objectives and Strategies for Using Derivatives As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest r ates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments. At March 31, 2024 and December 31, 2023, derivative assets were $84 and $70, respectively, and derivative liabilities were $210 and $259, respectively, primarily comprised of foreign currency exchange and commodity price contracts. Derivative assets are recorded in Other current assets or Other Assets, as appropriate, and derivative liabilities are recorded in Accrued expenses and other current liabilities or Other Liabilities, as appropriate. Foreign Currency Exchange Rate Risk Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowings. A portion of our balance sheet translation exposure for certain affiliates, which results from changes in translation rates between the affiliates’ functional currencies and the U.S. dollar, is hedged with cross-currency swap contracts and certain foreign denominated debt which are designated as net investment hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments. Derivative instruments are entered into to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated as cash flow hedges. Interest Rate Risk Interest rate risk is managed using a portfolio of variable and fixed-rate debt composed of short and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable and fixed-rate debt and are designated as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, and these contracts are designated as cash flow hedges. Commodity Price Risk We use derivative instruments, such as commodity forward and price swap contracts, to hedge a portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. In addition, we utilize negotiated contracts of varying durations along with strategic pricing mechanisms to manage volatility for a portion of our commodity costs. Fair Value Hedges Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these interest rate derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in Interest expense. The offset to the change in fair values of the related debt is also recorded in Interest expense. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to Interest expense over the life of the related debt. As of March 31, 2024, the aggregate notional values and carrying values of debt subject to outstanding interest rate contracts designated as fair value hedges were $525 and $475, respectively. For the three months ended March 31, 2024 and 2023, gains or losses recognized in Interest expense for interest rate swaps were not significant. Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same income statement line and period that the hedged exposure affects earnings. As of March 31, 2024, outstanding commodity forward and price swap contracts were in place to hedge a portion of our estimated requirements of the related underlying commodities in the remainder of 2024 and future periods. As of March 31, 2024, the aggregate notional value of outstanding foreign exchange derivative contracts designated as cash flow hedges was $3 billion. For the three months ended March 31, 2024 and 2023, no significant gains or losses were reclassified into Interest expense, Cost of products sold or Other (income) and expense, net as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At March 31, 2024, amounts to be reclassified from AOCI into Interest expense, Cost of products sold or Other (income) and expense, net during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at March 31, 2024 is March 2027. Net Investment Hedges For derivative instruments that are designated and qualify as net investment hedges, the aggregate notional value was $2 billion at March 31, 2024. We exclude the interest accruals on cross-currency swap contracts and the forward points on foreign exchange forward contracts from the assessment and measurement of hedge effectiveness. We recognize the interest accruals on cross-currency swap contracts in earnings within Interest expense. We amortize the forward points on foreign exchange contracts into earnings within Interest expense over the life of the hedging relationship. Changes in fair value of net investment hedges are recorded in AOCI and offset the change in the value of the net investment being hedged. For the three months ended March 31, 2024, unrealized gains of $27 related to net investment hedge fair value changes were recorded in AOCI and no significant amounts were reclassified from AOCI to Interest expense. No significant amounts were excluded from the assessment of net investment, fair value or cash flow hedge effectiveness as of March 31, 2024. Undesignated Hedging Instruments Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in Other (income) and expense, net. Losses of $23 and a gain of $8 were recorded in the three months ended March 31, 2024 and 2023, respectively. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At March 31, 2024, the notional value of these undesignated derivative instruments was approximately $2.6 billion.

Description Of Business Segment

Description Of Business Segments	3 Months Ended
Description Of Business Segments	Mar. 31, 2024
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information We are organized into operating segments based on product groupings. These operating segments have been aggregated into three reportable global business segments: Personal Care, Consumer Tissue and K-C Professional. The reportable segments were determined in accordance with how our chief operating decision maker and our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes Other (income) and expense, net and income and expense not associated with ongoing operations of the business segments, including the costs of corporate decisions related to the 2024 Transformation Initiative described in Note 2. The principal sources of revenue in each global business segment are described below: • Personal Care brands offer our consumers a trusted partner in caring for themselves and their families by delivering confidence, protection and discretion through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex and other brand names. • Consumer Tissue offers a wide variety of innovative solutions and trusted brands that responsibly improve everyday living for families around the world. Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Andrex, Viva, Scottex and other brand names. • K-C Professional partners with businesses to create Exceptional Workplaces, helping to make them healthier, safer and more productive through a range of solutions and supporting products such as wipers, tissue, towels, personal protective gear, soaps and sanitizers. Our brands, including Kleenex, Scott, WypAll, Kimtech and KleenGuard are well known for quality and trusted to help people around the world work better. Information concerning consolidated operations by business segment is presented in the following tables: Three Months Ended March 31 2024 2023 Change NET SALES Personal Care $ 2,713 $ 2,704 — Consumer Tissue 1,599 1,634 -2 % K-C Professional 823 847 -3 % Corporate & Other 14 10 N.M. TOTAL NET SALES $ 5,149 $ 5,195 -1 % OPERATING PROFIT Personal Care $ 545 $ 487 +12 % Consumer Tissue 290 240 +21 % K-C Professional 188 159 +18 % Corporate & Other (a) (151) (84) N.M. Other (income) and expense, net (a) 19 15 +27 % TOTAL OPERATING PROFIT $ 853 $ 787 +8 % (a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2024 Transformation Initiative. The first quarter 2024 Transformation Initiative charges related to the business segments were $12 in Personal Care, $4 in Consumer Tissue and $2 in K-C Professional. N.M. - Not Meaningful Sales of Principal Products: Three Months Ended March 31 (Billions of dollars) 2024 2023 Baby and child care products $ 1.8 $ 1.8 Consumer tissue products 1.6 1.6 Away-from-home professional products 0.8 0.8 All other 0.9 1.0 Consolidated $ 5.1 $ 5.2

Supplemental Balance Sheet Data

Supplemental Balance Sheet Data	3 Months Ended
Supplemental Balance Sheet Data	Mar. 31, 2024
Statement of Financial Position [Abstract]
Additional Financial Information Disclosure	Supplemental Balance Sheet Data The following schedule presents a summary of inventories by major class: March 31, 2024 December 31, 2023 LIFO Non-LIFO Total LIFO Non-LIFO Total Raw materials $ 117 $ 253 $ 370 $ 121 $ 292 $ 413 Work in process 123 84 207 116 95 211 Finished goods 552 645 1,197 520 692 1,212 Supplies and other — 310 310 — 311 311 792 1,292 2,084 757 1,390 2,147 Excess of FIFO or weighted-average cost over LIFO cost (207) — (207) (192) — (192) Total $ 585 $ 1,292 $ 1,877 $ 565 $ 1,390 $ 1,955 Inventories are valued at the lower of cost or net realizable value, determined on the FIFO or weighted-average cost methods, and at the lower of cost or market, determined on the LIFO cost method. The following schedule presents a summary of property, plant and equipment, net: March 31, 2024 December 31, 2023 Land $ 167 $ 149 Buildings 3,052 3,067 Machinery and equipment 15,064 15,132 Construction in progress 781 803 19,064 19,151 Less accumulated depreciation (11,292) (11,238) Total $ 7,772 $ 7,913

2024 Transformation Initiative

2024 Transformation Initiative (Tables)	3 Months Ended
2024 Transformation Initiative (Tables)	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following charges were incurred in connection with the 2024 Transformation Initiative: Three Months Ended March 31, 2024 Marketing, research and general expenses Charges for workforce reductions $ 23 Other exit costs 22 Total charges 45 Provision for income taxes (11) Net charges attributable to Kimberly-Clark Corporation $ 34 See Note 9 for charges by segment. The following summarizes the transformation initiative liabilities activity for the quarter: 2024 Transformation initiative liabilities at January 1 $ — Charges for workforce reductions and other cash exit costs 45 Cash payments (11) Transformation initiative liabilities at March 31 $ 34

Fair Value Information (Tables)

Fair Value Information (Tables)	3 Months Ended
Fair Value Information (Tables)	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair value of financial instruments	The following table includes the fair value of our financial instruments for which disclosure of fair value is required: Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value March 31, 2024 December 31, 2023 Assets Cash and cash equivalents (a) 1 $ 853 $ 853 $ 1,093 $ 1,093 Time deposits (b) 1 143 143 169 169 Liabilities Short-term debt (c) 2 7 7 2 2 Long-term debt (d) 2 7,963 7,412 7,982 7,569 (a) Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. (b) Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. (c) Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. (d) Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Mar. 31, 2024
Earnings Per Share [Abstract]
Average Common Shares Outstanding Basic and Diluted	The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows: Three Months Ended (Millions of shares) 2024 2023 Basic 336.9 337.5 Dilutive effect of stock options and restricted share unit awards 1.4 1.1 Diluted 338.3 338.6

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
Stockholders' Equity (Tables)	Mar. 31, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss), Attributable to Kimberly-Clark Corporation	The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows: Unrealized Translation Defined Benefit Pension Plans Other Postretirement Benefit Plans Cash Flow Hedges and Other Balance as of December 31, 2022 $ (2,769) $ (789) $ 52 $ (163) Other comprehensive income (loss) before reclassifications 95 (14) — (93) (Income) loss reclassified from AOCI — 7 (a) (1) (a) 15 Net current period other comprehensive income (loss) 95 (7) (1) (78) Balance as of March 31, 2023 $ (2,674) $ (796) $ 51 $ (241) Balance as of December 31, 2023 $ (2,678) $ (791) $ 39 $ (152) Other comprehensive income (loss) before reclassifications (144) 3 1 60 (Income) loss reclassified from AOCI — 8 (a) (1) (a) — Net current period other comprehensive income (loss) (144) 11 — 60 Balance as of March 31, 2024 $ (2,822) $ (780) $ 39 $ (92) (a) Included in computation of net periodic benefit costs.

Description Of Business Segme_2

Description Of Business Segments (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from External Customer
Information Concerning Consolidated Operations by Business Segment	Information concerning consolidated operations by business segment is presented in the following tables: Three Months Ended March 31 2024 2023 Change NET SALES Personal Care $ 2,713 $ 2,704 — Consumer Tissue 1,599 1,634 -2 % K-C Professional 823 847 -3 % Corporate & Other 14 10 N.M. TOTAL NET SALES $ 5,149 $ 5,195 -1 % OPERATING PROFIT Personal Care $ 545 $ 487 +12 % Consumer Tissue 290 240 +21 % K-C Professional 188 159 +18 % Corporate & Other (a) (151) (84) N.M. Other (income) and expense, net (a) 19 15 +27 % TOTAL OPERATING PROFIT $ 853 $ 787 +8 % (a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2024 Transformation Initiative. The first quarter 2024 Transformation Initiative charges related to the business segments were $12 in Personal Care, $4 in Consumer Tissue and $2 in K-C Professional. N.M. - Not Meaningful	[1]
Sales of Principal Products	Sales of Principal Products: Three Months Ended March 31 (Billions of dollars) 2024 2023 Baby and child care products $ 1.8 $ 1.8 Consumer tissue products 1.6 1.6 Away-from-home professional products 0.8 0.8 All other 0.9 1.0 Consolidated $ 5.1 $ 5.2

[1]Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2024 Transformation Initiative. The first quarter 2024 Transformation Initiative charges related to the business segments were $12 in Personal Care, $4 in Consumer Tissue and $2 in K-C Professional. N.M. - Not Meaningful

Summary of Balance Sheet Data (

Summary of Balance Sheet Data (Tables)	3 Months Ended
Summary of Balance Sheet Data (Tables)	Mar. 31, 2024
Statement of Financial Position [Abstract]
Schedule of Inventory, Current	The following schedule presents a summary of inventories by major class: March 31, 2024 December 31, 2023 LIFO Non-LIFO Total LIFO Non-LIFO Total Raw materials $ 117 $ 253 $ 370 $ 121 $ 292 $ 413 Work in process 123 84 207 116 95 211 Finished goods 552 645 1,197 520 692 1,212 Supplies and other — 310 310 — 311 311 792 1,292 2,084 757 1,390 2,147 Excess of FIFO or weighted-average cost over LIFO cost (207) — (207) (192) — (192) Total $ 585 $ 1,292 $ 1,877 $ 565 $ 1,390 $ 1,955
Property, Plant and Equipment	The following schedule presents a summary of property, plant and equipment, net: March 31, 2024 December 31, 2023 Land $ 167 $ 149 Buildings 3,052 3,067 Machinery and equipment 15,064 15,132 Construction in progress 781 803 19,064 19,151 Less accumulated depreciation (11,292) (11,238) Total $ 7,772 $ 7,913

Accounting Policies Narrative (

Accounting Policies Narrative (Details) - Net sales - Geographic Concentration Risk	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
K-C Argentina
Accounting Policies
Net sales of K-C Argentina, percent	1%	1%
Turkey
Accounting Policies
Net sales of K-C Argentina, percent	1%	1%

2024 Transformation Initiativ_2

2024 Transformation Initiative (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2026	Dec. 31, 2023
Restructuring Cost and Reserve
Income Tax Expense (Benefit)	$ (184)	$ (173)
2024 Transformation Initiative
Restructuring Cost and Reserve
Income Tax Expense (Benefit)	(11)
Restructuring Reserve	34			$ 0
Payments for Restructuring	11
Payments for Restructuring	(11)
2024 Transformation Initiative \| Maximum \| Scenario, Forecast
Restructuring Cost and Reserve
Expected Number of Positions Eliminated			5%
Expected Number of Positions Eliminated			5%
2024 Transformation Initiative \| Minimum \| Scenario, Forecast
Restructuring Cost and Reserve
Expected Number of Positions Eliminated			4%
Expected Number of Positions Eliminated			4%
2024 Transformation Initiative \| Workforce Reductions and Other Cash Exit Costs
Restructuring Cost and Reserve
Restructuring Charges	45
2024 Transformation Initiative \| Before Tax \| Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost			$ 1,500
Restructuring and Related Cost, Expected Cost			$ 1,500
2024 Transformation Initiative \| Before Tax \| Marketing, Research and General Expenses
Restructuring Cost and Reserve
Charges (adjustments) for workforce reductions	23
Other exit costs	22
Restructuring Charges	45
2024 Transformation Initiative \| After Tax \| Kimberly-Clark Corporation
Restructuring Cost and Reserve
Restructuring Charges	$ 34

Acquisition Narrative (Details)

Acquisition Narrative (Details) - USD ($) $ in Millions			3 Months Ended
Acquisition Narrative (Details) - USD ($) $ in Millions	Jun. 01, 2023	Feb. 24, 2022	Dec. 31, 2023	Jun. 30, 2023
Sale of Brazil tissue assets
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Gain (Loss) on Disposition of Business	$ 74
Costs Related to Divestiture	30
Proceeds from Divestiture of Businesses	212
Proceeds from Divestiture of Businesses	212
Gain (Loss) on Disposition of Business	74
Costs Related to Divestiture	30
Before Tax \| Sale of Brazil tissue assets
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Divestiture Net Benefit	44
Divestiture Net Benefit	44
After Tax \| Sale of Brazil tissue assets
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Divestiture Net Benefit	26
Divestiture Net Benefit	$ 26
Thinx Inc
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Business Combination, Consideration Transferred		$ 181
Sale of Stock, Percentage of Ownership after Transaction		58%
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions			30%	70%
Payments to Noncontrolling Interests			$ 47	$ 48

Acquisition (Schedule of Recogn

Acquisition (Schedule of Recognized Identified Assets Acquired and Liabilities Assumed) (Details) $ in Millions	Feb. 24, 2022 USD ($)
Thinx Inc
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Business Combination, Consideration Transferred	$ 181

Impairment of Intangible Asse_2

Impairment of Intangible Assets Narrative (Details) $ in Millions	3 Months Ended
	Jun. 30, 2023 USD ($)
Text Block [Abstract]
us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill - Softex - Before Tax	$ 593
us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill - Softex, Thinx, Inc. - Before Tax	658
us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill - Softex, Thinx, Inc. - After Tax	483
Intangible Assets Impaired, Fair Value Disclosure	$ 188

Fair Value Information (Narrati

Fair Value Information (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Redeemable Preferred Securities Of Subsidiaries Fair Value Disclosure	$ 26	$ 26
Fair Value, Measurements, Recurring \| Net Asset Value or Its Equivalent
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash Surrender Value, Fair Value Disclosure	69	67
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivatives Assets	84	70
Derivatives Liability	$ 210	$ 259

Fair Value Information (Fair Va

Fair Value Information (Fair Value Of Financial Instruments) (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Carrying (Reported) Amount, Fair Value Disclosure \| Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and cash equivalents	[1]	$ 853	$ 1,093
Time deposits	[2]	143	169
Carrying (Reported) Amount, Fair Value Disclosure \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Short-term debt	[3]	7	2
Long-term debt	[4]	7,963	7,982
Estimated Fair Value, Fair Value Disclosure \| Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and cash equivalents	[1]	853	1,093
Time deposits	[2]	143	169
Estimated Fair Value, Fair Value Disclosure \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Short-term debt	[3]	7	2
Long-term debt	[4]	$ 7,412	$ 7,569

[1] Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares shares in Millions	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Common shares outstanding	336.8	337.4

Earnings Per Share (Average Com

Earnings Per Share (Average Common Shares Outstanding Basic And Diluted) (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Average Common Shares Outstanding Basic and Diluted
Basic	336.9	337.5
Dilutive effect of stock options and restricted share unit awards	1.4	1.1
Diluted	338.3	338.6

Stockholders' Equity (Component

Stockholders' Equity (Components of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Unrealized currency translation adjustments		$ (149)	$ 93
Net current period other comprehensive income (loss)		(11)	8
Total Other Comprehensive Income (Loss), Net of Tax		(75)	7
Accumulated Other Comprehensive Income (loss)		(3,655)		$ (3,582)
Defined Benefit Pension Plans
Defined benefit and other postretirement benefit plans - Beginning balance		(791)	(789)
Other comprehensive income/(loss) before reclassifications		(3)	14
(Income)/loss reclassified from AOCI	[1]	8	7
Net current period other comprehensive income (loss)		(11)	7
Defined benefit and other postretirement benefit plans - Ending balance		(780)	(796)
Other Postretirement Benefit Plans
Defined benefit and other postretirement benefit plans - Beginning balance		39	52
Other comprehensive income/(loss) before reclassifications		1	0
(Income)/loss reclassified from AOCI	[1]	(1)	(1)
Net current period other comprehensive income (loss)		0	1
Defined benefit and other postretirement benefit plans - Ending balance		39	51
Unrealized Translation
Unrealized translation - Beginning balance		(2,678)	(2,769)
Other comprehensive income/(loss) before reclassifications		(144)	95
(Income)/loss reclassified from AOCI		0	0
Unrealized currency translation adjustments		(144)	95
Unrealized translation - Ending balance		(2,822)	(2,674)
Cash Flow Hedges and Other
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		60	(93)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0	15
Total Other Comprehensive Income (Loss), Net of Tax		60	(78)
Accumulated Other Comprehensive Income (loss)		$ (92)	$ (241)	$ (152)	$ (163)

[1]Included in computation of net periodic benefit costs.

Objectives And Strategies For_2

Objectives And Strategies For Using Derivatives (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Derivative Instruments, Gain (Loss)
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ 27
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss)
Gain (loss) on undesignated foreign exchange hedging instruments	(23)	$ 8
Foreign currency exchange contracts \| Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss)
Derivative, Notional Amount	2,600
Fair Value Hedging \| Interest Rate Contract
Derivative Instruments, Gain (Loss)
Long-term Debt, Fair Value	475
Derivative, Notional Amount	525
Cash Flow Hedging \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss)
Derivative, Notional Amount	3,000
Net Investment Hedging
Derivative Instruments, Gain (Loss)
Derivative, Notional Amount	2,000
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Derivative Instruments, Gain (Loss)
Derivative Asset	84		$ 70
Derivative Liability	$ 210		$ 259

Description Of Business Segme_3

Description Of Business Segments (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Net Sales		$ 5,149	$ 5,195
Sales Revenue, Net, Percent Change		(1.00%)
Operating Profit		$ 853	787
Other (income) and expense, net		$ 19	15
Operating Profit, Percent Change		8%
Personal Care
Net Sales		$ 2,713	2,704
Sales Revenue, Net, Percent Change		0%
Operating Profit		$ 545	487
Operating Profit, Percent Change		12%
Personal Care \| 2024 Transformation Initiative
Restructuring Charges		$ 12
Consumer Tissue
Net Sales		$ 1,599	1,634
Sales Revenue, Net, Percent Change		(2.00%)
Operating Profit		$ 290	240
Operating Profit, Percent Change		21%
Consumer Tissue \| 2024 Transformation Initiative
Restructuring Charges		$ 4
K-C Professional
Net Sales		$ 823	847
Sales Revenue, Net, Percent Change		(3.00%)
Operating Profit		$ 188	159
Operating Profit, Percent Change		18%
K-C Professional \| 2024 Transformation Initiative
Restructuring Charges		$ 2
Corporate and Other
Net Sales		14	10
Operating Profit	[1]	(151)	(84)
Other (income) and expense, net
Other (income) and expense, net	[1]	$ 19	$ 15
Operating Profit, Percent Change		27%

[1]Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2024 Transformation Initiative. The first quarter 2024 Transformation Initiative charges related to the business segments were $12 in Personal Care, $4 in Consumer Tissue and $2 in K-C Professional. N.M. - Not Meaningful

Description Of Business Segme_4

Description Of Business Segments Sales of Principle Products (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Consolidated
Net Sales	$ 5,149	$ 5,195
Consumer Tissue Products
Consolidated
Net Sales	1,600	1,600
Baby and Child Care Products
Consolidated
Net Sales	1,800	1,800
Away-from-home Professional Products
Consolidated
Net Sales	800	800
All Other
Consolidated
Net Sales	$ 900	$ 1,000

Supplemental Balance Sheet Da_2

Supplemental Balance Sheet Data - Inventory (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Raw materials	$ 370	$ 413
Work in process	207	211
Finished goods	1,197	1,212
Supplies and other	310	311
Inventory, Gross	2,084	2,147
Inventory, LIFO Reserve	207	192
Total	1,877	1,955
LIFO
Raw materials	117	121
Work in process	123	116
Finished goods	552	520
Supplies and other	0	0
Inventory, Gross	792	757
Inventory, LIFO Reserve	207	192
Total	585	565
Non-LIFO
Raw materials	253	292
Work in process	84	95
Finished goods	645	692
Supplies and other	310	311
Inventory, Gross	1,292	1,390
Inventory, LIFO Reserve	0	0
Total	$ 1,292	$ 1,390

Supplemental Balance Sheet Da_3

Supplemental Balance Sheet Data - Property Plant and Equipment (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment
Land	$ 167	$ 149
Buildings	3,052	3,067
Machinery and equipment	15,064	15,132
Construction in progress	781	803
Property, Plant and Equipment, Gross	19,064	19,151
Less accumulated depreciation	(11,292)	(11,238)
Total	$ 7,772	$ 7,913